15th week of 2010 patent applcation highlights part 49 |
Patent application number | Title | Published |
20100093599 | SHINE CONTROL CLEANSER - This invention relates to shine control cleansing compositions, which are capable of controlling the appearance of oily and shiny skin for an extended period of time. | 2010-04-15 |
20100093600 | REGULATION OF NEUROTRANSMITTERS SEQUESTRATION AND RELEASE THROUGH MANIPULATION OF THE VESICULAR FUNCTIONS - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 2010-04-15 |
20100093601 | COMPOSITIONS AND METHODS TO PROTECT CELLS BY BLOCKING ENTRY OF PATHOGEN PROTEINS - Pathogenic effector proteins which include one or more RxLR, dEER, Pexel or analogous motifs are blocked from entry into plant or animal cells by binding one or more of the motifs with a blocking compound which prevents binding of phosphoinositides or other polar lipids to the motifs which is a prerequisite for translocation of the pathogenic effector proteins into the plant or animal cell. The blocking compounds can take a variety of forms including synthetic peptides or the hydrophilic head-groups of phosphoinositides, phosphatidic acids, phospholipids, or sphingolipids. Suitable blocking compounds can be identified by assays demonstrating binding to RxLR, dEER, Pexel or analogous motifs. In addition, pathogenic effector proteins can be identified by analyzing whether they contain structural RxLR motifs using hidden markov modeling. | 2010-04-15 |
20100093602 | METHODS AND COMPOSITIONS FOR MODULATING ADHESION AND MIGRATION OF CADHERIN EXPRESSING CELLS - A method modulating adhesion and migration of at least one cadherin expressing cell includes administering a cadherin modulating agent to the at least one cadherin expressing cell in an amount effective to modulate cell adhesion and migration. The cadherin modulating agent includes a small molecule peptidomimetic of a peptide or cyclic peptide that comprises a cadherin cell adhesion recognition sequence. The cadherin modulating agent can promote or inhibit neurite outgrowth when applied to at least one neuron disposed on a substrate coated with a cadherin molecule. | 2010-04-15 |
20100093603 | USE OF ORGANIC COMPOUNDS - The invention relates to the use of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more active ingredient, for the manufacture of a medicament for the treatment of diabetic cardiomyopathy. | 2010-04-15 |
20100093604 | Gpr43 and modulators thereof for the treatment of metabolic-related disorders - The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. | 2010-04-15 |
20100093605 | PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME - Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome. | 2010-04-15 |
20100093606 | MRSA Bactericidal Topical Gel - I have combined Vancomycin at varying concentrations in a Calcium Alginate gel and treated open chronic wounds that cultured out MRSA. The response has been remarkable in the rapid cure of the involved wound. I have arrived at a 15% level of the Vancomycin as being an effective strength. The combined gel, if refrigerated, maintains it's effectiveness over three months. Only one to two applications results in negative cultures. | 2010-04-15 |
20100093607 | SYNERGISTIC THERAPEUTIC USE OF PROTHROMBIN COMPLEX CONCENTRATES WITH FVIII CONCENTRATES - The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, perk or post-operative bleeding. A novel treatment is proposed in which synergistic procoagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited. | 2010-04-15 |
20100093608 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES - Modified animal erythropoietin polypeptides and uses thereof are provide. | 2010-04-15 |
20100093609 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE - A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. Particular pharmaceutical species are 6-amino-4-methyl-8-(beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine, also known as TCN and by the trade name triciribine; as well as the 5′phosphate of triciribine. TCN and TCNP prodrugs of the present invention have increased bioavailability compared to the parent TCN and TCNP. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield TCN or TCNP, such that TCN or TCNP is delivered to the individual. | 2010-04-15 |
20100093610 | ROMIDEPSIN-BASED TREATMENTS FOR CANCER - The invention provides an improved process for preparing romidepsin. The process involves producing, purifying, or storing romidepsin under conditions that prevent the formation of undesired adducts. Purifying romidepsin at an apparent pH lower than approximately 6.0 (e.g., between an apparent pH of 4.0 and 6.0) has been discovered to prevent the reduction of the disulfide bond of romidepsin and the subsequent formation of dimerized, oligomerized, or polymerized adducts. The invention also provides pharmaceutical compositions of monomeric romidepsin free of dimerized, oligomerized, or polymerized adducts. | 2010-04-15 |
20100093611 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES - Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), I | 2010-04-15 |
20100093612 | INTEGRIN TARGETED CYCLOPEPTIDE LIGANDS, THEIR PREPARATION AND USE - The present invention relates to novel hybrid cyclopeptide compounds embodying pyrrolidine- or piperidine-based amino acid substructures grafted onto a RGD (-Arg-Gly-Asp-) tripeptide sequence and acting as targeting ligands towards integrin receptors, intended, for example, for the treatment of altered angiogenic phenomena or for the preparation of therapeutically and/or diagnostically useful compounds; the invention also concerns a process for the synthesis of said cyclopeptides and biologically active derivatives thereof. | 2010-04-15 |
20100093613 | METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OR STABILIZATION OF FIBROSIS - Agents that stabilize and/or prevent fibrosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on matrix deposition and remodeling, epithelial health, and inflammation. Treatment for fibrosis is provided using compositions of the invention. | 2010-04-15 |
20100093614 | Novel Composition for Tumor Growth Control - The invention describes a pharmaceutical composition comprising at least compound selected from the group of demethylating agents and HDAC inhibitors and at least one somatostatin analog or dopamine agonist for the treatment of a tumor which expresses a somatostatin and/or dopamine receptor. | 2010-04-15 |
20100093615 | ANTIBACTERIAL COMPOUNDS AND PROCESSES FOR ITS PRODUCTION - This invention relates to a novel antibiotic compounds, pharmaceutically acceptable salts and derivatives thereof, and to methods for obtaining such compounds. | 2010-04-15 |
20100093616 | Combination of EGF/GHRP-6 for Neurogeneration of Central Nervous System Following Autoimmune Damage - The present invention is directed to stimulate the neuroregeneration of the central nervous system due to autoimmune damage. In particular the pharmaceutical combination that comprise therapeutically effective concentrations of the Epidermal Growth Factor and the Growth Hormone Releasing Peptide-6, is administrated to a subject that suffers from symptoms of Multiple Sclerosis and Optic Neuromyelitis and corrects the demyelination caused by autoreactive cells in central nervous system. | 2010-04-15 |
20100093617 | Use - The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof. | 2010-04-15 |
20100093618 | POLYPEPTIDE CAPABLE OF INHIBITING HIV-1 TRANSCRIPTION AND REPLICATION AND USES THEREOF - A polypeptide inhibitor of transcription and replication of Human Immunodeficiency Virus (HIV-1), and related compositions and methods. | 2010-04-15 |
20100093619 | Insect Inhibition by Plant Serpin - The present invention relates to a method to limit damage by insects and mites in plants, by the use of endogenous plant proteinase inhibitors. More specifically, it relates to the use of serpins comprising an arginine residue in their reactive center loop, like | 2010-04-15 |
20100093620 | TYROSINE-RICH CONOPEPTIDES - The invention relates to relatively short peptides (termed Conopeptide-Y family peptides or CPY family peptides or CPY peptides herein), about 30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which are rich in the amino acid tyrosine. | 2010-04-15 |
20100093621 | SCGB3A2 AS A GROWTH FACTOR AND ANTI-APOPTOTIC AGENT - The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents. | 2010-04-15 |
20100093622 | METHOD OF PRODUCING NATIVE COMPONENTS, SUCH AS GROWTH FACTORS OR EXTRACELLULAR MATRIX PROTEINS, THROUGH CELL CULTURING OF TISSUE SAMPLES FOR TISSUE REPAIR - A medical composition is disclosed, which is injectable and which comprises a mixture of native components, which are obtainable by culturing one or more cell samples from a human or animal during normal conditions, said native components being included in the group consisting of growth factors, extracellular matrix proteins, and other substances produced by said cell samples during normal conditions, and a pharmaceutically acceptable carrier, as well as a method for producing the native components, a method for producing the medical composition, a method for treating a subject in need of tissue repair by injection of the medical composition, and use of said mixture of native components for the production of said medical composition for tissue repair via injection. A medical composition is disclosed, which is injectable and which comprises a mixture of native components, which are obtainable by culturing one or more cell samples from a human or animal during normal conditions, said native components being included in the group consisting of growth factors, extracellular matrix proteins, and other substances produced by said cell samples during normal conditions, and a pharmaceutically acceptable carrier, as well as a method for producing the native components, a method for producing the medical composition, a method for treating a subject in need of tissue repair by injection of the medical composition, and use of said mixture of native components for the production of said medical composition for tissue repair via injection. | 2010-04-15 |
20100093623 | COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF - Disclosed herein are compositions and methods relating to a peptide that inhibits Nod-like Receptors. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, arthritis, psoriasis, Alzheimer's disease, cardiovascular disease, diabetes, and sepsis. | 2010-04-15 |
20100093624 | PEPTIDE THERAPEUTICS THAT BIND VEGF AND METHODS OF USE THEREOF - The present invention provides peptides and mimetics thereof that bind to VEGF. In preferred embodiments, the peptides of the invention are D type optical isomers which can bind VEGF and which can inhibit or reduce VEGF biological activity. | 2010-04-15 |
20100093625 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE - Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention. | 2010-04-15 |
20100093626 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES IN DISEASE - A method of treating a neoplastic disorder in a subject includes administering to a Eph kinase expressing neoplastic cell of the subject being treated an EphA agonist and at least one immunosuppressant. | 2010-04-15 |
20100093627 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2010-04-15 |
20100093628 | METHODS OF TREATMENT USING WISP POLYPEPTIDES - The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide. | 2010-04-15 |
20100093629 | GENES AND POLYPEPTIDES RELATING TO HUMAN PANCREATIC CANCERS - The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against the disease. | 2010-04-15 |
20100093630 | MAMMALIAN CHEMOKINES; RELATED REAGENTS - Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits. | 2010-04-15 |
20100093631 | METHOD OF TREATING CRAVINGS BY ADMINISTRATION OF NERVE GROWTH FACTOR - A method for administering nerve growth factor to treat cravings is provided. Pharmaceutical compositions for the treatment of cravings comprising nerve growth factor are also provided. | 2010-04-15 |
20100093632 | ENAMEL MATRIX PROTEIN COMPOSITION FOR TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE - The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease. | 2010-04-15 |
20100093633 | POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY - The present invention relates to isolated polypeptides having antimicrobial activity. The invention also relates to polynucleotides encoding the polypeptides; and nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2010-04-15 |
20100093635 | Agonists of Guanylate Cyclase UseFul For The Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer. | 2010-04-15 |
20100093636 | METHODS OF TREATING INFLAMMATION - Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease, disorder, condition, or symptom. In some embodiments, the method comprises co-administering an agent that inhibits the interactions of PF4 and RANTES and a second active agent. | 2010-04-15 |
20100093637 | PEPTIDES AND USE THEREOF - The present invention relates to peptides, compositions containing such peptides, and the use thereof. The peptides derived from C-krox binding sequences of three zinc finger domains are effective for stimulating the collagen synthesis of normal human dermal fibroblast, and thus can be used to improve the appearance of the skin. | 2010-04-15 |
20100093638 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION - The present invention provides a method for the treatment of chemical substance abuse by selectively inhibiting ghrelin activity in humans comprising administering to a human in need thereof a therapeutically-effective amount of a ghrelin receptor ligand (GHS-RL). The ghrelin receptor ligand (GHS-RL) can be selected from the group consisting of a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA), and a ghrelin receptor partial agonist (GHS-RPA). More specifically, the invention provides a method for treating alcohol related disorders in humans comprising administering to a human in need thereof a therapeutically-effective amount of a compound which is a ghrelin receptor ligand (GHS-RL), such as a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA) and a ghrelin receptor partial agonist (GHS-RPA). | 2010-04-15 |
20100093639 | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides - This invention relates to novel transport molecules that comprise a polypeptide comprising amino acid residues arranged in a sequence that is the reverse-sequence of basic portion of the HIV-TAT protein. The novel transport polypeptides are useful for transmembrane or intracellular delivery of cargo molecules, non-limiting examples of which include polypeptides and nucleic acids. The novel transport polypeptides may be covalently or non-covalenty bound to the cargo molecules. | 2010-04-15 |
20100093640 | ACE-INHIBITORY PEPTIDES FROM WHEY AND METHODS FOR PROVIDING THE SAME - The invention relates to methods for providing compounds having an antihypertensive effect. More in particular, the invention relates to ACE (angiotensin I-converting enzyme)-inhibitory peptides that can be released enzymatically from whey proteins. Provided is a method for providing a protein hydrolysate having ACE-inhibitory activity, comprising treating a whey protein-containing substrate with a bacterial heat-labile neutral protease to produce a primary hydrolysate and treating said primary hydrolysate with a thermolysin to produce a secondary hydrolysate. Also provided are hydrolysates and isolated peptides obtainable by said method and uses thereof for the preparation of a medicament for inhibiting ACE activity in a mammal; for lowering the blood pressure; and/or for preventing the occurrence of hypertension. | 2010-04-15 |
20100093641 | SILK PROTEIN-MIMICKING PEPTIDES AND COMPOSITIONS FOR PREVENTING OR TREATING CRANIAL NEUROPATHIES COMPRISING THE SAME - The present invention relates to a silk protein-mimicking peptide represented by the following Formula 1, a composition for preventing or treating a brain disease, a composition for improving a brain or cognitive function and a composition for preventing or treating diseases, disorders or conditions associated with oxidative stress comprising the peptide: | 2010-04-15 |
20100093642 | NOVEL POLYPEPTIDES - The present invention relates to novel polypeptides, nucleic acids encoding said peptides, cell lines, vectors, pharmaceutical compositions and antibodies. The invention may be used to treat fungus, infections, ulcers, wounds, cancer and/or inflammation in a patient in need thereof. | 2010-04-15 |
20100093643 | CARDIOPROTECTIVE COMPOUNDS - Tissue protective compounds comprise the tetrapeptide structure A-B-C-D wherein each hydrogen of the N-terminus NH2 of amino acid residue A may independently optionally be replaced by C1-S alkyl or C1-S acyl, A—is an aromatic amino acid residue wherein the aromatic ring may optionally be substituted with one or more nitro group, B—is a diamino acid residue wherein the side chain amino group is substituted with C1-S acyl, C1-S alkyl, 'B′-Ci-s acyl or —B′-Ci-s alkyl, wherein B′ is an an amino acid residue which may optionally be substituted with one or more nitro group, C—is Gly wherein the peptide N—H may optionally be changed to N-methyl, D—is Phe which is substituted on the aromatic ring with at least one nitro group and optionally further substituted on the aromatic ring with one or more group independently selected from nitro, fluoro, chloro, bromo, iodo, CF3 or CN, wherein the peptide N—H may optionally be changed to N-methyl, and the C-terminus C═O of amino acid residue D is substituted with NH2, NHC1-5 alkyl, NH—NH2, NH—NHC1-5 alkyl, or 0-C1-S alkyl, or the C-terminus is COOH or CH2OH, or a pharmaceutically acceptable salt thereof. | 2010-04-15 |
20100093644 | TEMPLATE-FIXED PEPTIDOMIMETICS - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 4 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to agonize or to antagonize GPCR receptors such as CXCR3, urotensin and CCR10. They can be used as medicaments to treat or prevent diseases such as cardiovascular disorders, dermatological disorders, endocrine system and hormone disorders, metabolic diseases, inflammatory diseases, neurological diseases, respiratory diseases, haematological diseases and cancer. These β-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy. | 2010-04-15 |
20100093645 | SMAC Peptidomimetics and the Uses Thereof - The invention relates to peptidomimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these peptidomimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis. | 2010-04-15 |
20100093646 | METHOD FOR ENHANCING MEMORY IN NORMAL INDIVIDUAL - The present invention provides a method for enhancing memory in a normal individual, particularly in an individual of middle or advanced age who is regarded as clinically normal. The method for enhancing memory in a normal individual comprises administration of a peptide consisting of Leu and Ile or a modified form thereof. | 2010-04-15 |
20100093647 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS - A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent. | 2010-04-15 |
20100093648 | TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS - The invention relates to compositions and methods for preventing or treating a macular degeneration-related disorder, comprising a scyllo-inositol compound or pharmaceutically acceptable salts thereof. | 2010-04-15 |
20100093649 | Synthetic glycolipid analogues and derivatives for the treatment of pathologic disorders - The present invention describes compositions and methods for synthetic analogues and derivatives of β-glycolipids. These analogues and derivatives may be used for the treatment, amelioration or prevention of a pathological disorder. They may also be used for the modulation of the Th1/Th2 cell balance toward an anti-inflammatory or pro-inflammatory response, resulting in the treatment, amelioration or prevention of immune-related disorders. | 2010-04-15 |
20100093650 | Pharmaceutical Anit-Infective Composition for Inhalation - A composition for inhalation, comprising at least: a) an effective amount of an antimicrobial aminoglycoside derivative or a salt thereof, and b) an effective amount of a biofilm modifier which is a macrolide derivative or a salt thereof. | 2010-04-15 |
20100093651 | Artemisinin Derivatives - This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as | 2010-04-15 |
20100093652 | Preservative System for Emulsion-Based Therapeutic Topical Formulations - A topical formulation that inhibits the growth of microorganisms comprises an effective amount of an insecticide dissolved in an oil phase comprising a water-miscible or water-soluble surface active agent, a suspending agent, and a non-ionic surfactant, and an aqueous phase comprising one or more preservatives, where the aqueous phase is buffered to a specific pH. The overall antimicrobial efficacy in an emulsion formulation can be enhanced by buffering the aqueous phase of the emulsion to a pH at which the preservative system inhibits growth for a wider variety of microorganism types in the formulation relative to the equivalent formulation in which the aqueous phase is not buffered. | 2010-04-15 |
20100093653 | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions - A compound of formula (I) or a polymorphic form thereof can be used for the preparation of a cosmetic or dermato logical composition for the treatment of skin ageing. | 2010-04-15 |
20100093654 | TETRASUBSTITUTED CLUCOPYRANOSYLATED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Tetrasubstituted glucopyranosylated benzene derivatives of general formula (I) as defined according to claim | 2010-04-15 |
20100093655 | USE OF RILUZOLE AND DERIVATIVES THEREOF FOR PRODUCING NEW DRUGS - The present invention relates to the use of riluzole or pharmaceutically acceptable salts of riluzole in the production of drugs for restoring and amplifying the immune function in the treatment of infectious diseases and cancers. | 2010-04-15 |
20100093656 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS - This invention relates to novel phosphate-modified nucleosides, and methods for producing them, being useful for the prevention or treatment of a viral infection in a mammal, and for preparing oligonucleotides by DNA/RNA polymerase-dependent amplification, e.g. PCR. | 2010-04-15 |
20100093657 | LOW GLYCEMIC MIXTURES - The present invention relates to a food compound comprising an emulsion containing triglyceride oils as well as a low-glycemic saccharose isomer. | 2010-04-15 |
20100093658 | Therapeutic Agent For Metabolic Syndrome and Food Containing the Therapeutic Agent - It is an object of the invention to provide a novel therapeutic agent that can reduce visceral fat accumulation to prevent or treat metabolic syndrome. In order to achieve this object, the invention provides a therapeutic agent for metabolic syndrome that comprises, as an active ingredient, dietary fiber aggregation in which water-soluble β-glucan has the highest content. Particularly effective as the water-soluble β-glucan is water-soluble β-glucan having a β-1,3 glycoside bond and β-1,4 glycoside bond in the same molecule. | 2010-04-15 |
20100093659 | POLYVALENT BIOCONJUGATES - The present invention is directed to conjugates for biorecognition comprising (i) an carbohydrate backbone structure (PO) of 5 to 20 monosaccharide units, (ii) oligosaccharide biorecognition groups (Bio) of 1 to 10 monomer units, (iii) a bifunctional spacer groups of the formula -(y)p-(S)q-(z)r-, wherein S is a spacer group, p, q and r are each 0 or 1, whereby at least one of p and r is different from 0, and y and z are chemoselective ligation groups, which covalently link a said Bio group to said backbone structure, and the degree of conjugation, indicating the average number of covalently attached Bio biorecognition groups per monomer unit of the backbone, being from 0.2 to 1. The invention is also directed to processes for their preparation, intermediates for use in the process as well as use of said conjugates, especially for inhibiting pathogenic bacteria. | 2010-04-15 |
20100093660 | ANTI-TUMOR COMPOSITION COMPRISING TISSUE-ACCUMULATING CHITOSAN GEL - The present invention is achieved based on a novel finding that chitosan gel having retentivity in tissue has an antitumor activity and provides an antitumor composition containing chitosan gel having retentivity in tissue. The chitosan gel having retentivity in tissue of the present invention is preferably chitosan gel formed of a chitosan derivative having a carbohydrate chain introduced thereto as a base, to which a photoreactive group is further introduced to form crosslink with photo-irradiation; or chitosan gel formed of a polyion complex, which is formed of a carbohydrate chain-containing chitosan derivative and another substance, for example, an acidic polysaccharide. The antitumor composition of the present invention can suppress growth of a tumor without bringing it into contact with the tumor but by simply arranging it near the tumor. | 2010-04-15 |
20100093661 | COMPOSITION COMPRISING CHITOSAN AND AN ACIDIC DRUG FOR ORAL CONTROLLED RELEASE - The present invention relates to a composition comprising an aqueous solvent and a conjugate of at least one hydrophilic polymer having a primary amine functional group, a derivative or monomer thereof and at least one acidic drug; a method for its preparation and use thereof. | 2010-04-15 |
20100093662 | NOVEL AMPHIPHILIC CYCLODEXTRIN DERIVATIVES - The present invention relates to cyclodextrins having the following formula (I): to nanostructures comprising them, to processes for preparing them, to the use thereof, and also to compositions comprising them. | 2010-04-15 |
20100093663 | Sulfoalkyl Ether Cyclodextrin Compositions - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. | 2010-04-15 |
20100093664 | COMPOSITIONS USEFUL FOR REDUCING NEPHROTOXICITY AND METHODS OF USE THEREOF - The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug. | 2010-04-15 |
20100093665 | SILYLATED PIPERIDINE DERIVATIVES - Compounds of formula I: I wherein at least one of R4 and R5 comprises Si(R6)3 as a substituent selectively attenuate production of Aβ(1-42) and hence find use in treatment of Alzheimer's disease and related conditions. | 2010-04-15 |
20100093666 | WATER-STABILIZED ANTIMICROBIAL ORGANOSILANE PRODUCTS, COMPOSITIONS, AND METHODS FOR USING THE SAME - The present invention relates to water-stable compositions and compounds formed by mixing an organosilane, optionally having a non-hydrolyzable organic group, but having one or more hydrolyzable groups, and an acidified stabilizing solution prepared from at least one acid, at least one glycol ether, and at least one cationic surfactant, preferably at least one quaternary ammonium salt (QAS), in water. The present invention also relates to methods of treating a substrate by mixing or contacting the substrate with the product, compound, or composition of this invention for a period of time sufficient for treatment of the substrate, methods of antimicrobially treating a food article, methods of antimicrobially coating a fluid container, methods of dyeing and treating a substrate, and methods of antimicrobially coating a latex medical article. The invention also pertains to a treated substrate having adhered thereto the product, compound, or composition of this invention. | 2010-04-15 |
20100093667 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts. | 2010-04-15 |
20100093668 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS - The disclosure relates to a compound of formula (I): | 2010-04-15 |
20100093669 | METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM - Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed. | 2010-04-15 |
20100093670 | Compounds for the treatment of angiogenesis - The invention relates to isoxazole, isothiazole, and triazole compounds that are useful for treating or inhibiting angiogenesis. | 2010-04-15 |
20100093671 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders. | 2010-04-15 |
20100093672 | USE OF S1P RECEPTOR MODULATOR - Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. | 2010-04-15 |
20100093673 | PAIN RELIEVING PATCH - Described here are patches for the treatment of pain. The patches include a carrier material, which itself, in the absence of an active agent, is capable of relieving pain. Methods of treating pain using the patches are also described. | 2010-04-15 |
20100093674 | Skin cancer prevention method and product - The increased use of sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. According to the present invention, the beneficial effects of UV radiation are obtained by incorporating vitamin D into the topical after-sun lotions and creams, applied to the skin after exposure to the sun to prevent its harmful effects. Application of the after-sun product provides vitamin D, which is activated by the skin to calcitriol for cancer prevention. Because calcitriol also promotes cellular growth and differentiation, the topical after-sun product with vitamin D may be of benefit for photoaging. | 2010-04-15 |
20100093675 | NOVEL METHOD - There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound. | 2010-04-15 |
20100093676 | POLYAPHRON TOPICAL COMPOSITION WITH VITAMIN D - A topical composition comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion and at least one vitamin D or vitamin D analogue. | 2010-04-15 |
20100093677 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS - The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, Synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof. | 2010-04-15 |
20100093678 | Compositions and methods of the treatment of obesity and osteoporosis - The present invention relates to naturally occurring compositions comprising vitamin D3 or related analog and methods for treating obesity and/or osteoporosis and reducing body fat or enhancing a bone graft in patients in need thereof. | 2010-04-15 |
20100093679 | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY - A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6β,7β;15β;16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form. | 2010-04-15 |
20100093681 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR - The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions. | 2010-04-15 |
20100093682 | LIPID COMPOSITION HAVING EXCELLENT SHAPE RETENTION PROPERTY AND PRODUCT - It is to provide a technique for preventing aggregation or caking of menthol at the time of its keeping. In addition, it is to provide a lipid composition, which can show excellent thermal stability even in the case of high temperature at the time of keeping menthol and at the time of blending in a product, does not cause mutual aggregation of powders, particles, flakes, pellets, sticks and the like of menthol, and can maintain its shape retention property. From 10 to 50% by mass of sterols are added to and mixed with from 50 to 90% by mass of menthol, and the resultant is melted with heating. Paraffins may be further added and mixed in an amount of 20% by mass or less, based on the lipid composition. | 2010-04-15 |
20100093683 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH A PROTEASOME INHIBITOR - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2010-04-15 |
20100093684 | SYNERGISTIC INTERACTION OF NOTCH-1 INHIBITORS WITH GLUCOCORTICOIDS - The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors. | 2010-04-15 |
20100093685 | NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof | 2010-04-15 |
20100093686 | COATINGS WITH CRYSTALLIZED ACTIVE AGENT(S) AND METHODS - Coatings with crystallized active agent(s) and related methods are disclosed. One method includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. Also disclosed is an elution control coating which includes active agent that is at least about 80% crystallized within one week of being disposed on a medical device. One method enhances the formation of active agent crystals within a coating layer by adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. Another method includes increasing the rate of active agent nucleation within the coating. | 2010-04-15 |
20100093687 | Method Of Treating Disorder Related To High Cholesterol Concentration - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 2010-04-15 |
20100093688 | Porphyrin catalysts and methods of use thereof - This invention provides a novel class of substituted macrocyclic porphyrin compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described. | 2010-04-15 |
20100093689 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS - The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y | 2010-04-15 |
20100093690 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS - Compounds of formula I | 2010-04-15 |
20100093691 | TOPICAL FORMULATIONS - There is provided topical pharmaceutical compositions comprising compounds of formula I | 2010-04-15 |
20100093692 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN - The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient. | 2010-04-15 |
20100093693 | MODULATORS OF CELLULAR ADHESION - The present invention provides compounds having formula (I); | 2010-04-15 |
20100093694 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2010-04-15 |
20100093695 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors - This invention discloses novel gamma secretase inhibitors of the formula: | 2010-04-15 |
20100093696 | 2-AMINO PYRIMIDINE COMPOUNDS - The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors. | 2010-04-15 |
20100093697 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists - The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression. | 2010-04-15 |
20100093698 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Heteroaryl Compounds of formula (I): | 2010-04-15 |
20100093699 | COMPOUNDS AND USES THEREOF - 177 - This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence, and neurodegenerative disorders. | 2010-04-15 |
20100093700 | Methods of Treating Mood Disorders - A method of treating at least one symptom or condition associated with but not limited to: Mood Disorders including but not limited to a) Depressive Disorders, including but not limited to, Major Depressive Disorder and Dysthymic Disorder and b) Bipolar Depression and/or Bipolar mania including but not limited to Bipolar I Disorder, including but not limited to those with manic, depressive or mixed episodes, and Bipolar II Disorder, c) Cyclothymic Disorder, and d) Mood Disorder Due to a General Medical Condition, comprising administering an effective amount of formula (I) or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of formula (I) or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent. | 2010-04-15 |